Table 2 Treatment dose data for patient dogs with spontaneous intra-axial masses

First diagnosis (days before treatment)

16

35

35

33

28

Pre-treatment diagnosis

Vascular neoplasm vs vascular anomaly

Astrocytoma^†

Low-grade glioma

Glial neoplasm

Astrocytoma^†

Infused activity (GBq)

0.0183

0.0478

0.0351

0.0414

0.0486

–

–

Treatment days post-calibration

11

5

10

5

8

Volume of embolic (mL)

0.0014

0.00076

0.0021

0.00066

0.0017

Pre-treatment mass vol (mL)

2.76

5.82

3.53

8.66

8.48

–

–

Single compartment dose (Gy)

34.9

63.7

45

45.2

62.2

–

–

Dosimetry method

PET/CT

PET/CT

PET/CT

PET/CT

PET/CT

MicroCT

MicroCT

Mass

Mean dose (Gy)

45.5

57.6

58.1

45.4

64.1

76.7

11.3

D10 (Gy)

95.2

122.9

91.5

94.8

137.0

131.4

19.3

D30 (Gy)

58.6

70.2

70.8

54.9

80.0

80.8

11.9

D50 (Gy)

35.7

37.6

55.8

36.1

52.6

59.4

8.73

D70 (Gy)

22.6

20.2

41.6

24.2

27.9

44.8

6.58

D90 (Gy)

8.5

10.0

26.9

8.1

7.2

30.6

4.49

V30

58.3

55.9

85.4

60.4

68.9

90.6

3.28

V50

37.2

40.6

57.8

34.5

52.6

62.4

0.96

V60

28.9

34.9

44.0

26.8

43.5

49.3

0.64

V80

16.5

26.3

20.3

15.8

30.0

30.6

0.34

V100

9.1

19.0

6.4

8.4

19.3

10.3

0.22

Hemisphere

Mean dose (Gy)

33.8

65.3

41.1

45.0

61.4

41.4

6.08

V20

54.8

74.6

68.2

65.5

77.5

63.1

3.39

V30

40.8

66.4

57.6

50.8

67.1

49.8

1.21

V50

23.0

52.2

37.1

33.6

49.8

28.8

0.39

V60

17.3

44.7

27.7

27.3

41.7

21.5

0.27

Cortex

Mean dose (Gy)

15.4

27.6

19.2

16.7

33.3

–

–

V20

24.1

33.3

32.6

24.1

43.8

–

–

V30

17.7

28.2

25.6

17.7

36.5

–

–

V50

10.1

21.3

15.3

10.7

25.5

–

–

V60

7.4

18.0

11.3

8.3

21.0

–

–

T:N^‡

2.96

2.08

3.02

2.71

1.93

–

–